Clinical Trial Update: Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial comparing iguratimod plus low-dose rituximab to low-dose rituximab alone in corticosteroid-resistant or relapsed immune thrombo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Iguratimod (iguratimod)
• Rituxan (rituximab)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Immune Thrombocytopenia (ITP) | Phase 2 | Status: NOT_YET_RECRUITING